{Reference Type}: Journal Article
{Title}: Rapid and Reliable HLA-B*59:01 Genotyping to Prevent Carbonic Anhydrase Inhibitor-Induced Severe Cutaneous Adverse Reactions.
{Author}: Huh JY;Song YJ;Park G;
{Journal}: Ann Clin Lab Sci
{Volume}: 54
{Issue}: 1
{Year}: 2024 Jan
{Factor}: 1.18
{Abstract}: <B>OBJECTIVE: </B>Carbonic anhydrase inhibitors (CAIs) are intraocular pressure-reducing medications used in ophthalmology. Human leukocyte antigen-B*59:01 (HLA-B*59:01) is strongly associated with CAI-induced severe cutaneous adverse reactions (SCARs). This study aimed to develop and validate a rapid and economical screening method for HLA-B*59:01 to prevent carbonic anhydrase inhibitor-induced SCARs.<BR><B>METHODS: </B>Duplex allele-specific polymerase chain reaction (PCR) with an internal control was performed for HLA-B*59:01 genotyping. The accuracy of duplex allele-specific PCR for HLA-B*59:01 genotyping was evaluated in 200 blood samples, using sequence-based typing (SBT) as the reference method.<BR><B>RESULTS: </B>In total, 50 HLA-B*59:01-positive and 150 HLA-B*59:01-negative results obtained using duplex allele-specific PCR were in complete agreement with the SBT results.<BR><B>CONCLUSIONS: </B>Duplex allele-specific PCR is a rapid, reliable, and economical assay for screening the HLA-B*59:01 allele.